19 October 2020 - Neurelis today that the U.S. FDA has granted extended expiration dating for the company's lead product, Valtoco (diazepam nasal spray). 

Valtoco was approved by the FDA on 10 January 2020, for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in adult and paediatric patients 6 years of age and older. 

Read Neurelis press release